The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Gold compounds as therapeutic agents for human diseases
Abstract
The application of gold in medicine is traceable for several thousand years and Au(i) compounds have been used clinically to treat rheumatoid arthritis since the last century. Recently research into gold-based drugs for a range of human diseases has seen a renaissance. Old as well as new Au(i) and Au(iii) compounds have been used and designed with an aim of targeting cellular components that are implicated in the onset or progression of cancers, rheumatoid arthiritis, viral and parasitic diseases. In addition, new disease targets have been found for gold compounds that have given insight into the mechanism of action of these compounds, as well as in the molecular pathophysiology of human diseases. Here we discuss the rationale for the design and use of gold compounds that have specific and selective targets in cells to alleviate the symptoms of a range of human diseases. We summarise the most recent findings in this research and our own discoveries to show that gold compounds can be developed to become versatile and powerful drugs for diseases caused by dysfunction of selenol and thiol containing proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Physiological functions of thioredoxin and thioredoxin reductase
Arnér, E. S. J., & Holmgren, A. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01701.x · Cited by 2,525
Mitochondrial Membrane Potential in Living Cells
Chen, L. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.001103 · Cited by 1,037
Shaw, C. F. (1999) · Chemical Reviews · doi:10.1021/cr980431o · Cited by 990
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
Hickey, J. L., Ruhayel, R. A., Barnard, P. J., Baker, M. V., Berners-Price, S. J., & Filipovska, A. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804027j · Cited by 599
Self-citationThioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Bindoli, A., Rigobello, M. P., Scutari, G., Gabbiani, C., Casini, A., & Messori, L. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.026 · Cited by 595
Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells
Modica-Napolitano, J. S., & Aprille, J. R. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00125-9 · Cited by 576
Human Placenta Thioredoxin Reductase
Gromer, S., Arscott, L. D., Williams, C. H., Schirmer, R. H., & Becker, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20096 · Cited by 536
Zhong, L., Arnér, E. S. J., & Holmgren, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100114897 · Cited by 527
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
The thioredoxin system—From science to clinic
Gromer, S., Urig, S., & Becker, K. (2004) · Medicinal Research Reviews · doi:10.1002/med.10051 · Cited by 479
Felson, D. T., Anderson, J. J., & Meenan, R. F. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780331001 · Cited by 470
Gladyshev, V. N., Jeang, K. T., & Stadtman, T. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.6146 · Cited by 468
Zhang, Z.-Y. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.083001.144616 · Cited by 433
Targeting the mitochondrial cell death pathway with gold compounds
Barnard, P. J., & Berners-Price, S. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.04.006 · Cited by 417
Self-citationMarzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A., & Rigobello, M. P. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.12.021 · Cited by 415
Metal based drugs: from serendipity to design
Fricker, S. P. (2007) · Dalton Transactions · doi:10.1039/b705551j · Cited by 414
Inhibition of HIV Fusion with Multivalent Gold Nanoparticles
Bowman, M.-C., Ballard, T. E., Ackerson, C. J., Feldheim, D. L., Margolis, D. M., & Melander, C. (2008) · Journal of the American Chemical Society · doi:10.1021/ja710321g · Cited by 371
Kuntz, A. N., Davioud-Charvet, E., Sayed, A. A., Califf, L. L., Dessolin, J., Arnér, E. S. J., & Williams, D. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040206 · Cited by 365
The thioredoxin-thioredoxin reductase system: over-expression in human cancer.
Lincoln, D. T., Emadi, E. M. A., Tonissen, K. F., & Clarke, F. M. (2003) · PubMed · Cited by 337
Mitochondria as therapeutic targets for cancer chemotherapy
Galluzzi, L., Larochette, N., Zamzami, N., & Kroemer, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209598 · Cited by 337
Milacic, V., Chen, D., Ronconi, L., Landis-Piwowar, K. R., Fregona, D., & Dou, Q. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3017 · Cited by 317
Krauth‐Siegel, R. L., Bauer, H., & Schirmer, R. H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200300639 · Cited by 302
Mirabelli, C. K., Johnson, R. K., Sung, C. M., Faucette, L. F., Muirhead, K. A., & Crooke, S. T. (1985) · PubMed · Cited by 295
Medical uses of gold compounds: Past, present and future
Pricker, S. P. (1996) · Gold Bulletin · doi:10.1007/bf03215464 · Cited by 279
Casini, A., Hartinger, C., Gabbiani, C., Mini, E., Dyson, P. J., Keppler, B. K., & Messori, L. (2008) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2007.11.003 · Cited by 267
Zhong, L., Arnér, E. S. J., Ljung, J., Åslund, F., & Holmgren, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8581 · Cited by 263
Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase
Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Björnstedt, M., Bindoli, A., Sturaro, A., Rella, R., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.07.023 · Cited by 252
McKeage, M. J., Maharaj, L., & Berners-Price, S. J. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00048-6 · Cited by 243
Self-citationArscott, L. D., Gromer, S., Schirmer, R. H., Becker, K., & Williams, C. H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3621 · Cited by 232
Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase
Jeon, K.-I., Jeong, J.-Y., & Jue, D.-M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5981 · Cited by 226
Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions
Pia Rigobello, M., Messori, L., Marcon, G., Agostina Cinellu, M., Bragadin, M., Folda, A., Scutari, G., & Bindoli, A. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.020 · Cited by 213
Undressing of Phosphine Gold( I ) Complexes as Irreversible Inhibitors of Human Disulfide Reductases
Urig, S., Fritz‐Wolf, K., Réau, R., Herold‐Mende, C., Tóth, K., Davioud‐Charvet, E., & Becker, K. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502756 · Cited by 206
Rundlöf, A.-K., & Arnér, E. S. J. (2004) · Antioxidants & Redox Signaling · doi:10.1089/152308604771978336 · Cited by 195
Wang, Y., He, Q.-Y., Sun, R. W.-Y., Che, C.-M., & Chiu, J.-F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2867 · Cited by 190
Rackham, O., Nichols, S. J., Leedman, P. J., Berners-Price, S. J., & Filipovska, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.022 · Cited by 186
Self-citationBerners-Price, S. J., & Sadler, P. J. (1988) · Structure and Bonding · doi:10.1007/3-540-50130-4_2 · Cited by 184
Self-citationCyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons
Yan, J. J., Chow, A. L.-F., Leung, C.-H., Sun, R. W.-Y., Ma, D.-L., & Che, C.-M. (2010) · Chemical Communications · doi:10.1039/c001216e · Cited by 179
Induction of mitochondrial permeability transition by auranofin, a Gold(I)‐phosphine derivative
Rigobello, M. P., Scutari, G., Boscolo, R., & Bindoli, A. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704823 · Cited by 178
Sannella, A. R., Casini, A., Gabbiani, C., Messori, L., Bilia, A. R., Vincieri, F. F., Majori, G., & Severini, C. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.028 · Cited by 172
Anestål, K., & Arnér, E. S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210733200 · Cited by 172
Alger, H. M., & Williams, D. L. (2002) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(02)00031-2 · Cited by 172
Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit
Jeon, K.-I., Byun, M.-S., & Jue, D.-M. (2003) · Experimental & Molecular Medicine · doi:10.1038/emm.2003.9 · Cited by 169
Anti-cancer potential of gold complexes
Tiekink, E. R. T. (2008) · Inflammopharmacology · doi:10.1007/s10787-007-0018-5 · Cited by 166
Cox, A. G., Brown, K. K., Arner, E. S. J., & Hampton, M. B. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.021 · Cited by 165
Milacic, V., & Dou, Q. P. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.032 · Cited by 163
Rigobello, M. P., Scutari, G., Folda, A., & Bindoli, A. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.038 · Cited by 158
Stallings‐Mann, M. L., Jamieson, L., Regala, R. P., Weems, C. R., Murray, N. R., & Fields, A. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3405 · Cited by 154
Inhibition of the DNA‐binding activity of NF‐κB by gold compounds in vitro
Yang, J.-P., Merin, J. P., Nakano, T., Kato, T., Kitade, Y., & Okamoto, T. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00157-5 · Cited by 149
Gold(III) compounds as anticancer drugs
Gabbiani, C., Casini, A., & Messori, L. (2007) · Gold bulletin · doi:10.1007/bf03215296 · Cited by 142
Rigobello, M. P., Callegaro, M. T., Barzon, E., Benetti, M., & Bindoli, A. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(97)00216-5 · Cited by 138
Handel, M. L., Watts, C. K. W., DeFazio, A., Day, R. O., & Sutherland, R. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4497 · Cited by 134
Saggioro, D., Rigobello, M. P., Paloschi, L., Folda, A., Moggach, S. A., Parsons, S., Ronconi, L., Fregona, D., & Bindoli, A. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.08.016 · Cited by 133
Omata, Y., Folan, M., Shaw, M., Messer, R. L. W., Lockwood, P. E., Hobbs, D. T., Bouillaguet, S., Sano, H., Lewis, J. B., & Wataha, J. C. (2006) · Toxicology in Vitro · doi:10.1016/j.tiv.2006.01.012 · Cited by 129
Gold(I)-Mediated Inhibition of Protein Tyrosine Phosphatases: A Detailed in Vitro and Cellular Study
Krishnamurthy, D., Karver, M. R., Fiorillo, E., Orrù, V., Stanford, S. M., Bottini, N., & Barrios, A. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800101w · Cited by 127
Bioinorganic and medicinal chemistry: aspects of gold(i)-protein complexes
Bhabak, K. P., Bhuyan, B. J., & Mugesh, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01057j · Cited by 127
Rackham, O., Shearwood, A.-M. J., Thyer, R. T., McNamara, E. L., Davies, S. M. K., Callus, B. A., Miranda‐Vizuete, A., Berners‐Price, S. J., Cheng, Q., Arnér, E. S. J., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.015 · Cited by 126
Self-citationKataoka, K., Handa, H., & Nishizawa, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105383200 · Cited by 125
Vergara, E., Casini, A., Sorrentino, F., Zava, O., Cerrada, E., Rigobello, M. P., Bindoli, A., Laguna, M., & Dyson, P. J. (2009) · ChemMedChem · doi:10.1002/cmdc.200900370 · Cited by 125
Interaction of Gold(I) with the Active Site of Selenium-Glutathione Peroxidase
Chaudière, J., & Tappel, A. L. (1984) · Journal of Inorganic Biochemistry · doi:10.1016/0162-0134(84)85030-8 · Cited by 119
Smart, D. D., Ortiz, K. L., Mattson, D., Bradbury, C. M., Bisht, K. S., Sieck, L., Brechbiel, M. W., & Gius, D. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3990 · Cited by 117
Bondeson, J. (1997) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(96)00419-3 · Cited by 116
Inhibitory effects of a new oral gold compound on hela cells
Simon, T. M., Kunishima, D. H., Gj, V., & LORBER, A. (1979) · Cancer · Cited by 116
Huaizhi, Z., & Yuantao, N. (2001) · Gold bulletin · doi:10.1007/bf03214805 · Cited by 113
Yan, K., Lok, C., Bierła, K., & Che, C. (2010) · Chemical Communications · doi:10.1039/c0cc01058h · Cited by 110
The Escherichia coli Copper-responsivecopA Promoter Is Activated by Gold
Stoyanov, J. V., & Brown, N. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200580200 · Cited by 105
Lehman, A. J., Esdaile, J. M., Klinkhoff, A. V., Grant, E., Fitzgerald, A. A., Canvin, J., & The METGO Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21018 · Cited by 103
Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι
Erdogan, E., Lamark, T., Stallings‐Mann, M. L., Jamieson, L., Pellechia, M., Thompson, E. A., Johansen, T., & Fields, A. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606054200 · Cited by 103
Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct
Jackson-Rosario, S., Cowart, D. M., Myers, A. G., Tarrien, R. J., Levine, R. L., Scott, R. A., & Self, W. T. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0466-z · Cited by 89
Wang, Y., He, Q., Che, C., & Chiu, J. (2005) · PROTEOMICS · doi:10.1002/pmic.200402027 · Cited by 87
Gunatilleke, S. S., & Barrios, A. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060158f · Cited by 84
Gold compounds for rheumatoid arthritis
Sutton, B. M. (1986) · Gold bulletin · doi:10.1007/bf03214639 · Cited by 77
Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma
Lum, C. T., Yang, Z. F., Li, G. H., Sun, R. W., Fan, S. T., Poon, R. T. P., Lin, M. C. M., Che, C., & Kung, H. F. (2005) · International Journal of Cancer · doi:10.1002/ijc.21484 · Cited by 77
Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead
Wang, Y., He, Q., Sun, R. W., et al. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.034 · Cited by 76
Overexpression of thioredoxin reductase 1 regulates NF‐κB activation
Sakurai, A., Yuasa, K., Shoji, Y., Himeno, S., Tsujimoto, M., Kunimoto, M., Imura, N., & Hara, S. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10377 · Cited by 73
Caruso, F., Rossi, M., Tanski, J. M., Pettinari, C., & Marchetti, F. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204690 · Cited by 66
Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells
Rigobello, M. P., Folda, A., Dani, B., Menabò, R., Scutari, G., & Bindoli, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.026 · Cited by 65
Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds
Engman, L., McNaughton, M., Gajewska, M., Kumar, S., Birmingham, A., & Powis, G. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200606000-00007 · Cited by 54
Suresh, D., Balakrishna, M. S., Rathinasamy, K., Panda, D., & Mobin, S. M. (2008) · Dalton Transactions · doi:10.1039/b804026p · Cited by 51
Smith, P. F., Hoke, G. D., Alberts, D. W., Bugelski, P. J., Lupo, S., Mirabelli, C. K., & Rush, G. F. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23520-0 · Cited by 51
Wang, Y., He, Q., Che, C., Tsao, S. W., Sun, R. W., & Chiu, J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.11.024 · Cited by 47
Caruso, F., Villa, R., Rossi, M., Pettinari, C., Paduano, F., Pennati, M., Daidone, M. G., & Zaffaroni, N. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.11.018 · Cited by 46
Lum, C. T., Liu, X., Sun, R. W., Li, X., Peng, Y., He, M., Kung, H. F., Che, C., & Lin, M. C. M. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.01.033 · Cited by 45
Inhibition of Selenium Metabolism in the Oral Pathogen Treponema denticola
Jackson-Rosario, S., & Self, W. T. (2009) · Journal of Bacteriology · doi:10.1128/jb.00164-09 · Cited by 43
Traber, K. E., Okamoto, H., Kurono, C., Baba, M., Saliou, C., Soji, T., Packer, L., & Okamoto, T. (1999) · International Immunology · doi:10.1093/intimm/11.2.143 · Cited by 40
Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis
Lum, C. T., Huo, L., Sun, R. W., Li, M., Kung, H. F., Che, C., & Lin, M. C. M. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.537693 · Cited by 34
Treatment of HIV associated psoriatic arthritis with oral gold.
Shapiro, D. L., & Masci, J. R. (1996) · PubMed · Cited by 32
Cited by
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs
Liu, W., & Gust, R. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35314h · Cited by 762
Chemical biology of anticancer gold(iii) and gold(i) complexes
Zou, T., Lum, C. T., Lok, C.-N., Zhang, J.-J., & Che, C.-M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00132c · Cited by 628
N-Heterocyclic carbene metal complexes in medicinal chemistry
Oehninger, L., Rubbiani, R., & Ott, I. (2013) · Dalton Trans. · doi:10.1039/c2dt32617e · Cited by 560
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Binding of transition metal ions to albumin: Sites, affinities and rates
Bal, W., Sokołowska, M., Kurowska, E., & Faller, P. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.06.018 · Cited by 489
Metadata
- Authors
- Berners-Price, S. J., & Filipovska, A.
- Venue
- Metallomics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011
- Volume
- 3
- Issue
- 9
- Pages
- 863
- ISSN
- 1756-5901 (ISSN-L)
- 1756-591X
- OpenAlex
- W2095157449
- Cited by
- 495
- References
- 89
- FWCI
- 15.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.